BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 31478786)

  • 1. Selected Mutations by Nemonoxacin and Fluoroquinolone Exposure Among Relevant Gram-Positive Bacterial Strains in Taiwan.
    Yang JJ; Cheng A; Tai HM; Chang LW; Hsu MC; Sheng WH
    Microb Drug Resist; 2020 Feb; 26(2):110-117. PubMed ID: 31478786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Vitro Resistance Development to Nemonoxacin in Streptococcus pneumoniae: A Unique Profile for a Novel Nonfluorinated Quinolone.
    Roychoudhury S; Makin K; Twinem T; Leunk R; Hsu MC
    Microb Drug Resist; 2016 Oct; 22(7):578-584. PubMed ID: 27267788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.
    Yang JC; Lee PI; Hsueh PR
    Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1369-75. PubMed ID: 20658256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nemonoxacin has potent activity against gram-positive, but not gram-negative clinical isolates.
    Li ZX; Liu YN; Wang R; Li AM
    Clin Ter; 2015; 166(6):e374-80. PubMed ID: 26794819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
    Lauderdale TL; Shiau YR; Lai JF; Chen HC; King CH
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1338-42. PubMed ID: 20065058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of Type II Topoisomerase Mutations to Fluoroquinolone Resistance in Enterococcus faecium from Japanese Clinical Setting.
    Urushibara N; Suzaki K; Kawaguchiya M; Aung MS; Shinagawa M; Takahashi S; Kobayashi N
    Microb Drug Resist; 2018; 24(1):1-7. PubMed ID: 28504916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones.
    Grohs P; Houssaye S; Aubert A; Gutmann L; Varon E
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3542-7. PubMed ID: 14576115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic mutations in the quinolone resistance-determining region are related to changes in the epidemiological profile of methicillin-resistant Staphylococcus aureus isolates.
    de Oliveira TLR; Cavalcante FS; Chamon RC; Ferreira RBR; Dos Santos KRN
    J Glob Antimicrob Resist; 2019 Dec; 19():236-240. PubMed ID: 31176072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
    Adam HJ; Laing NM; King CR; Lulashnyk B; Hoban DJ; Zhanel GG
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4915-20. PubMed ID: 19738018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones.
    Yamada M; Yoshida J; Hatou S; Yoshida T; Minagawa Y
    Br J Ophthalmol; 2008 Jun; 92(6):848-51. PubMed ID: 18460536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro Activity of Sitafloxacin and Additional Newer Generation Fluoroquinolones Against Ciprofloxacin-Resistant Neisseria gonorrhoeae Isolates.
    Hamasuna R; Ohnishi M; Matsumoto M; Okumura R; Unemo M; Matsumoto T
    Microb Drug Resist; 2018; 24(1):30-34. PubMed ID: 28581359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of WQ-3810, a novel fluoroquinolone, against multidrug-resistant and fluoroquinolone-resistant pathogens.
    Kazamori D; Aoi H; Sugimoto K; Ueshima T; Amano H; Itoh K; Kuramoto Y; Yazaki A
    Int J Antimicrob Agents; 2014 Nov; 44(5):443-9. PubMed ID: 25239276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibacterial activities of nemonoxacin against clinical isolates of Staphylococcus aureus: an in vitro comparison with three fluoroquinolones.
    Li Z; Liu Y; Wang R; Li A
    World J Microbiol Biotechnol; 2014 Nov; 30(11):2927-32. PubMed ID: 25129332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fluoroquinolone resistance determining region mutation in Streptococcus pneumonia isolates].
    Zhang FF; Zhao CJ; Wang H
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Dec; 36(12):940-4. PubMed ID: 24503427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro development of resistance to DX-619 and other quinolones in enterococci.
    Wickman PA; Black JA; Smith Moland E; Thomson KS; Hanson ND
    J Antimicrob Chemother; 2006 Dec; 58(6):1268-73. PubMed ID: 17062613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of plasmid-mediated quinolone resistance and mutations in the gyrase and topoisomerase IV genes in Salmonella isolated from 12 tertiary-care hospitals in Korea.
    Jeong HS; Kim JA; Shin JH; Chang CL; Jeong J; Cho JH; Kim MN; Kim S; Kim YR; Lee CH; Lee K; Lee MA; Lee WG; Shin JH; Lee JN
    Microb Drug Resist; 2011 Dec; 17(4):551-7. PubMed ID: 21830947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of DNA gyrase and topoisomerase IV mutations in fluoroquinolone resistance of Capnocytophaga spp. clinical isolates and laboratory mutants.
    Ehrmann E; Jolivet-Gougeon A; Bonnaure-Mallet M; Fosse T
    J Antimicrob Chemother; 2017 Aug; 72(8):2208-2212. PubMed ID: 28453633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterisation of the quinolone resistance-determining regions (QRDR) including gyrA, gyrB, parC and parE genes in Streptococcus pneumoniae.
    Kakinuma Y; Maeda Y; Mason C; Goldsmith CE; Coulter WA; Matsuda M; Dooley JS; Lowery CJ; Moore JE
    Br J Biomed Sci; 2012; 69(3):123-5. PubMed ID: 23057160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in the gyrB, parC, and parE genes of quinolone-resistant isolates and mutants of Edwardsiella tarda.
    Kim MS; Jun LJ; Shin SB; Park MA; Jung SH; Kim K; Moon KH; Jeong HD
    J Microbiol Biotechnol; 2010 Dec; 20(12):1735-43. PubMed ID: 21193831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.